Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments

This study has been completed.
Sponsor:
Information provided by:
Mid Atlantic Retina
ClinicalTrials.gov Identifier:
NCT01255293
First received: December 6, 2010
Last updated: June 13, 2013
Last verified: June 2013

December 6, 2010
June 13, 2013
November 2010
October 2012   (final data collection date for primary outcome measure)
Retinal redetachment rate [ Time Frame: Six months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01255293 on ClinicalTrials.gov Archive Site
  • Best-corrected visual acuity [ Time Frame: 6 and 12 months ] [ Designated as safety issue: No ]
  • Silicone oil emulsification rate [ Time Frame: Monthly ] [ Designated as safety issue: No ]
    Gonioscopy examination will be used at monthly postoperative visits to assess silicone oil emulsification in each patient.
Same as current
Not Provided
Not Provided
 
Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments
A Prospective, Randomized Study Comparing 1000 Centistoke and 5000 Centistoke Silicone Oil Tamponade for Repair of Proliferative Vitreoretinopathy Retinal Detachments and Diabetic Tractional Retinal Detachments

The purpose of this study is to assess the retinal redetachment rates with 1000 centistoke versus 5000 centistoke silicone oil tamponade for repair of complex retinal detachments.

As part of retinal detachment surgery, the eye is typically filled with a gas bubble or silicone oil bubble. This bubble acts like a balloon inside the eye and helps to keep the retina pushed back against the eye wall so it can heal in its proper place. Gas bubbles spontaneously dissolve over a few weeks whereas silicone oil remains in the eye until removed with another surgery. When retinal detachments are associated with significant scar tissue on the retinal surface, silicone oil is often used since it can remain filling the eyeball for as long as necessary to help the retina to heal properly in place. Currently, two different types of silicone oil (1000 centistoke and 5000 centistoke) are commercially available and have been approved for use in the eye by the Food and Drug Administration. The goal of the study is to compare the outcomes using these two different types of silicone oil.

The retinal detachment will be repaired in a standard fashion. There will be no difference between the way retinal detachments are repaired in this study compared to those not in this study. Patients will be randomly assigned (like a flip of a coin) to receive one of the types of silicone oil. Both types of oil have very similar characteristics. The primary difference is that one type is thicker (more viscous) than the other, analogous to honey in comparison with maple syrup.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Retinal Detachment
  • Vitrectomy
  • Proliferative Vitreoretinopathy
  • Diabetic Retinopathy
  • Procedure: 1000 centistoke silicone oil
    Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 1000 centistoke silicone oil.
  • Procedure: 5000 centistoke silicone oil
    Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 5000 centistoke silicone oil
  • Active Comparator: 1000 centistoke silicone oil
    Intervention: Procedure: 1000 centistoke silicone oil
  • Active Comparator: 5000 centistoke silicone oil
    Intervention: Procedure: 5000 centistoke silicone oil
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
15
October 2012
October 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Presence of rhegmatogenous retinal detachment or tractional retinal detachment due to grade C or worse proliferative vitreoretinopathy or proliferative diabetic retinopathy.
  • Judgment by the investigator that silicone oil tamponade is surgically indicated for appropriate repair of the complex retinal detachment.
  • Visual acuity of light perception or better.
  • Ability to provide written informed consent and comply with study assessments for the full duration of the study.

Exclusion Criteria:

  • Inability to re-attach the retina at the time of surgery.
  • Prior trabeculectomy or tube shunt surgery.
  • Corneal opacity which limits visualization of the trabecular meshwork.
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01255293
MAR-3
No
Jason Hsu, Mid Atlantic Retina
Mid Atlantic Retina
Not Provided
Principal Investigator: Jason Hsu, MD Mid Atlantic Retina
Mid Atlantic Retina
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP